India is seeing an unhealthy rise in cases of the chronic disease affecting kids, but awareness and resources remain low.…
US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro pen, its widely used diabetes and weight-loss…
In a recent interview, Samantha Ruth Prabhu shared how her blood sugar levels spiked despite eating clean, until she tried…
Liver diseases are rising sharply in India due to poor lifestyle, diabetes, and self-medication. Expert warns that even youth are…
This Father’s Day, make health a priority. Doctor recommends 14 simple tests for dads over 60 to catch hidden problems…
A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, offering hope…
A new study links high insulin levels to irregular periods in women, suggesting blood sugar issues—not just hormones—could be behind…
Cataracts are a common reason for blurry vision, especially as we age. But eye experts say other serious conditions like…
Sugar Boards in CBSE schools will educate students about the risks associated with consuming excessive sugar and discuss healthier dietary…
Can diabetics eat mangoes or watermelon? Yes, in moderation. Learn how portion control, smart food pairings, and mindful eating can…
Malnutrition-related diabetes mellitus aka type 5 diabetes has been recently recognised as a form of the non-communicable disease. But is…
Heart attacks and strokes are among the most common and devastating complications of diabetes.
Earlier studies have linked obesity with 13 types of cancer, many of which are also more common in people with…
Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP and GLP-1 receptors, which…
American Heart Association (AHA) recommends less than 25 grams (6 teaspoons) of sugar per day for children ages 2 to…
Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus.
Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists can be integrated…
Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.